Online Data Supplement

Longitudinal assessment of lung function in Swiss childhood cancer survivors

Rahel Kasteler*, Maria Otth*, Florian S Halbeisen, Luzius Mader, Florian Singer,

Nicolas X von der Weid, Marc Ansari, Jochen Rössler, Claudia E Kuehni

*Authors contributed equally to this work

Corresponding author:

Prof. Claudia E. Kuehni, MD MSc

Swiss Childhood Cancer Registry Institute of Social and Preventive Medicine University of Bern Mittelstrasse 43 3012 Bern Switzerland

E-mail: claudia.kuehni@ispm.unibe.ch

Supplementary Explanation E1 Explanation of multivariable linear mixed regression analysis with random intercept and random slope

The multivariable linear mixed regression analysis with random intercept and random slope allows to take clustering and longitudinal changes of tests from each patient into account.

Here we explain the data output with the example of FEV1:

The upper part of the table describes the FEV1 z-scores at time "zero", which refers to the time at diagnosis. It can be considered as the extrapolated baseline FEV1 z-score, where each patient starts at diagnosis. The reference patient (female, with lymphoma, no radiotherapy, no chemotherapy, no HSCT and no thoracic surgery) starts at a z-score of -1.07. If a person is male (z-score estimate 0.16) and additionally received thoracic radiotherapy (z-score estimate 0.16), he starts at a modelled FEV1 z-score of -0.75 (-1.07 (baseline) + 0.16 (difference female to male) + 0.16 (difference from no radiotherapy to radiotherapy)).

The lower part of the table describes the change of FEV1 z-scores per year. The reference patient (female, with lymphoma, no radiotherapy, no chemotherapy, no HSCT and no thoracic surgery) has an annual increase in FEV1 z-score of 0.09. For a male person (z-score estimate -0.07) exposed to thoracic radiotherapy (z-score estimate -0.05) the annual change in FEV1 z-score would be -0.03.

With this approach the starting point (intercept) and annual decrease (slope) can be calculated for patients with different diagnoses and exposure to different lung toxic treatment modalities.

2

Supplementary Table E1 Lung function in childhood cancer survivors exposed to lung-toxic therapies on the last test when all five outcomes were measured by z-scores and percentage predicted at the same time (N=128)

	Survivors		
	n	%	median (IQR)
Time from diagnosis to last test with all five outcome parameters	127		5.0 (3.1 – 7.0)
Age at last PFT (median, IQR [years])	127		16.8 (12.4 – 19.2)
FEV1			
FEV1 z-score	127		-1.0 (-2.0 – -0.1)
FEV1 z-score <-1.645	41	32	-2.5 (-3.2 – -2.0)
FEV1 % predicted	127		88.4 (76.8 – 98.7)
FEV1 <80%predicted	38	30	68.7 (61.3 – 74.8)
FVC			
FVC z-score	127		-1.1 (-2.1 – -0.2)
FVC z-score <-1.645	47	37	-2.6 (-3.3 – -2.0)
FVC % predicted	127		87.1 (76.0 – 98.1)
FVC <80% predicted	44	35	68.5 (62.3 – 76.1)
FEV1/FVC			
FEV1/FVC z-score	127		0.2 (-0.4 – 1.1)
FEV1/FVC z-score <-1.645	5	4	-2.3 (-2.6 – -1.9)
FEV1/FVC % predicted	127		101.0 (97.2 – 106.7)
FEV1/FVC <0.7	3	2	78.2 (67.7 – 79.9)
FEV1/FVC <0.7 and FEV1<80%predicted	2	2	n.a.
FEV1/FVC <0.7 and FEV1 z-score <-	3	2	n.a.
1.645	C C	-	
TLC			
TLC z-score	127		-0.6 (-1.4– 0.04)
TLC z-score <-1.645	24	19	-2.2 (-3.1 – -1.9)
TLC % predicted	127		92.6 (81.8 – 100.5)
TLC <75% predicted	18	14	67.6 (50.2 - 73.2)
TLC <75% predicted and FEV1 \ge 80% predicted	2	2	n.a.
DLCO			
DLCO z-score	127		-0.7 (-1.5 – 0.5)
DLCO z-score <-1.645	29	23	-2.4 (-3.4 – -1.8)
DLCO % predicted	127	-	89.7 (78.9 – 106.8)
DLCO <75% predicted ^c	17	14	60.1 (53.5 – 69.2)
FEV1, FVC, TLC or DLCO z-score < -1.645	63	50	n.a.

Abbreviations: IQR, interquartile range; PFT, pulmonary function test

Supplementary Table E2 FEV1 z-scores in childhood cancer survivors exposed to pulmotoxic treatment compared to GLI 2012 reference values, secondary analysis including age at cancer diagnosis; multivariable linear mixed regression adjusted for all covariates in the model (180 subjects, 760 tests)

	Estimate	95% CI	p-value *
Intercept (FEV1 z-score at time of diagnosis †)	-0.13	-1.57 1.30	
Sex (ref. female)	0.09	-0.38 0.56	0.707
BMI (ref. healthy: z-score ≥ -2, ≤ 1)			0.458
Underweight (z-score < -2)	-0.3	-0.79 0.09	
Overweight (z-score $\geq 1, \leq 2$)	0.05	-0.43 0.52	
Obese (z-score > 2)	0.10	-0.54 0.73	
Cancer diagnosis (ref. lymphoma)			0.119
CNS tumor	-0.001	-0.77 0.76	
Bone tumors	-1.30	-2.55 -0.06	
Germ cell tumors	1.27	-0.05 2.60	
Leukemia	-0.77	-1.97 0.43	
Neuroblastoma	-1.39	-3.27 0.49	
Renal tumors	0.25	-1.52 1.03	
Soft tissue sarcoma	-0.80	-1.98 0.38	
Age at diagnosis (ref. 0 - 4 years)			
5 - 13 years	-0.81	-1.71 0.10	0.004
>13 years	-0.96	-1.89 -0.04	
Thoracic radiotherapy (ref. no)	0.13	-0.87 1.14	0.794
Chemotherapy (ref. no)	-0.39	-0.92 0.14	0.150
HSCT (ref. no)	0.17	-0.64 1.00	0.678
Thoracic surgery (ref. no)	-1.04	-1.98 -0.11	0.029
Change of FEV1 z-score per year Time since diagnosis (continuous, per year)	0.06	-0.19 0.31	
Interaction male sex	-0.07	-0.15 0.01	0.103
Interaction BMI (ref. healthy: z-score ≥ -2, ≤ 1)	0.01	0.10 0.01	0.953
Underweight (z-score < -2)	0.003	-0.15 0.16	0.000
Overweight (z-score $\geq 1, \leq 2$)	0.003	-0.09 0.10	
Obese (z-score > 2)	0.04	-0.10 0.17	
Interaction cancer diagnosis (ref. lymphoma)	0101	00	0.059
CNS tumor	-0.07	-0.20 0.06	
Bone tumors	0.16	-0.05 0.36	
Germ cell tumor	-0.27	-0.51 -0.05	
Leukemia	0.12	-0.08 0.33	
Neuroblastoma	0.29	-0.04 0.61	
Renal tumors	-0.05	-0.23 0.13	
Soft tissue sarcoma	0.01	-0.20 0.19	
Age at diagnosis (ref. 0 - 4 years)	0101	0.20 0.10	0.047
5 - 13 years	-0.02	-0.15 0.11	
>13 years	0.09	-0.05 0.23	
Interaction thoracic radiotherapy (ref. no)	-0.05	-0.24 0.14	0.582
Interaction chemotherapy (ref. no)	0.11	0.01 0.20	0.027
Interaction HSCT (ref. no)	-0.16	-0.27 0.002	0.046
Interaction thoracic surgery (ref. no)	-0.04	-0.19 0.12	0.639
	0.04	0.10 0.12	0.000

Abbreviations: CNS, central nervous system; HSCT, hematopoietic stem cell transplantation

* Likelihood ratio test p-value indicating whether the characteristic explains differences in FEV1 within the study population.

[†] Reference patient corresponds to a female person, at diagnosis, diagnosed with lymphoma, and not exposed to thoracic radiotherapy, chemotherapy, HSCT, and thoracic surgery.

Supplementary Table E3 FVC z-scores in childhood cancer survivors exposed to pulmotoxic treatment compared to GLI 2012 reference values secondary analysis including age at cancer diagnosis; multivariable linear mixed regression adjusted for all covariates in the model (178 subjects, 758 tests)

$\begin{array}{cccccccccccccccccccccccccccccccccccc$
$\begin{array}{c} 0.360\\ 0.18\\ 0.21\\ 0.71\\ 0.402\\ 0.61\\ 0.94\\ 2.53\\ 0.98\\ 0.62\\ 1.31\\ 0.55\\ 0.339\\ 0.33\\ 0.20\\ \end{array}$
$\begin{array}{c} 0.360\\ 0.18\\ 0.21\\ 0.71\\ 0.402\\ 0.61\\ 0.94\\ 2.53\\ 0.98\\ 0.62\\ 1.31\\ 0.55\\ 0.339\\ 0.33\\ 0.20\\ \end{array}$
0.18 0.21 0.71 0.402 0.61 0.94 2.53 0.98 0.62 1.31 0.55 0.339 0.33 0.20
0.21 0.71 0.402 0.61 0.94 2.53 0.98 0.62 1.31 0.55 0.339 0.33 0.20
0.71 0.402 0.61 0.94 2.53 0.98 0.62 1.31 0.55 0.339 0.33 0.20
0.402 0.61 0.94 2.53 0.98 0.62 1.31 0.55 0.339 0.33 0.20
0.61 0.94 2.53 0.98 0.62 1.31 0.55 0.339 0.33 0.20
0.94 2.53 0.98 0.62 1.31 0.55 0.339 0.33 0.20
2.53 0.98 0.62 1.31 0.55 0.339 0.33 0.20
0.98 0.62 1.31 0.55 0.339 0.33 0.20
0.62 1.31 0.55 0.339 0.33 0.20
1.31 0.55 0.339 0.33 0.20
0.55 0.339 0.20
0.339 0.33 0.20
0.33 0.20
0.20
1.11 0.121
0.63 0.535
0.29 0.232
-0.55 0.001
0.00
0.33
0.02 0.168
0.101
0.07
0.18
0.18
0.126
0.02
0.07
-0.004
0.17
0.42
0.42 0.0001
0.42 0.0001 0.09
0.42 0.0001
0.42 0.0001 0.09 0.046
0.42 0.0001 0.09 0.046 0.09
0.42 0.0001 0.09 0.046 0.09 0.19
0.42 0.0001 0.09 0.046 0.09 0.19 0.05 0.188
0.02 0.168 0.101 0.07 0.18 0.18 0.126 0.02 0.07 -0.004

Abbreviations: CNS, central nervous system; HSCT, hematopoietic stem cell transplantation

* Likelihood ratio test p-value indicating whether the characteristic explains differences in FEV₁ within the study population.

⁺ Reference patient corresponds to a female person, at diagnosis, diagnosed with lymphoma, and not exposed to thoracic radiotherapy, chemotherapy, HSCT, and thoracic surgery.

	Diagnosis	Year of diagnosis	Age at first thoracic surgery [years]	Relapse	Description of thoracic surgery/ surgeries	Additional lung toxic exposure ¹
1	(VIa) Nephroblastoma	1992	6.6	Yes	Thoracotomy, resection upper lobe left side, resection lower lobe right side	Mediastinal radiotherapy
2	(IIb) Non-Hodgkin Iymphoma	1995	13.7	No	Laminectomy Th2-Th5	Craniospinal irradiation
3	(VIIIc) Ewing tumor	1995	5.6	Yes	Rib resection, resection of lingula	Whole lung irradiation
4	(IIb) Non-Hodgkin Iymphoma	1996	16.4	Yes	Thoracotomy, en bloc resection upper lobe left side	Mediastinal radiotherapy, busulfan, autologous HSCT
5	(VIa) Nephroblastoma	1998	6.3	Yes	Thoracotomy, resection lower lobe right side	Whole lung irradiation, autologous HSCT
6	(Xc) Malignant gonadal germ cell tumors	1999	15.3	No	Thoracotomy, resection upper lobe left side	Mediastinal radiotherapy, bleomycin
7	(VIa) Nephroblastoma	2000	2.3	Yes	Thoracotomy, wedge resection	Whole lung irradiation
8	(VIIIc) Ewing tumor	2001	10.0	Yes	Rib resection 7-9, Thoracotomy for resection of metastasis	Whole lung irradiation
9	(IIa) Hodgkin lymphoma	2001	15.1	No	Thoracoscopy, biopsy	Mantle irradiation, bleomycin
10	(VIIIc) Ewing tumor	2002	14.3	No	Thoracotomy, resection lower lobe left side, metastasectomy	Whole lung irradiation, autologous HSCT
11	(VIIIc) Ewing tumor	2003	13.5	No	Rib resection (6 th rib)	Radiotherapy other
12	(IXd) Other specified soft tissue sarcoma	2003	8.3	No	Thoracotomy, resection lower lobe left side, resection of pleura and part of the diaphragm	Whole lung irradiation
13	(VIIIc) Ewing tumor	2004	4.9	Yes	Rib resection (rib 9-10)	Chest irradiation, autologous HSCT
14	(VIIIc) Ewing tumor	2004	13.9	Yes	Rib resection (rib 3-9), partial resection of the diaphragm	Radiotherapy other, autologous HSCT
15	(IIa) Hodgkin lymphoma	2006	16.8	Yes	Thoracoscopy, biopsy	Mediastinal radiotherapy, autologous HSCT
16	(VIIIc) Ewing tumor	2007	12.9	Yes	Thoracotomy, tumor resection, rib resection (9 th rib)	
17	(VIIIc) Ewing tumor	2009	14.6	Yes	Thoracotomy, wedge resection, rib resection (rib 8-9)	Whole lung irradiation, autologous HSCT
18	(IXd) Other specified soft tissue sarcoma	2009	8.1	No	Thoracotomy, metastasectomy	Whole lung irradiation
19	(IXa) Rhabdomyosarcoma	2012	14.6	Yes	Thoracotomy, tumor resection, partial rib resection (rib 3-5)	Radiotherapy other

Supplementary Table E4 Description of childhood cancer survivors treated with thoracic surgery, N=19



Supplementary Figure E1 Flow chart of study population

*Including the following centers with pediatric oncology units: Kinderklinik Kantonsspital Aarau AG, Universitäts-Kinderspital Basel, Universitäts-Kinderklinik Inselspital Bern, Hospital des Enfants Geneve, CHUV Lausanne, Kinderklinik Kantonsspital Luzern, Ostschweizer Kinderspital St. Gallen, Universitäts-Kinderspital Zürich

† Pulmotoxic treatment defined as chemotherapy with busulfan, bleomycin, lomustine or carmustine and/or chest radiotherapy